UniProt ID: P09874
Gene: PARP1
Molecular Weight: 113 kDa
Subcellular Localization: Nucleus (primary), mitochondrial under stress
Protein Family: PARP family (17 members)
Key Domains:
PARP1 (Poly(ADP-Ribose) Polymerase 1) is a nuclear enzyme that plays a central role in DNA damage detection and repair, chromatin remodeling, and transcriptional regulation[1]. It is the founding and most abundant member of the PARP family, accounting for approximately 85% of cellular poly(ADP-ribosyl)ation activity[2]. In neurodegeneration, PARP1 hyperactivation contributes to neuronal death through NAD+ depletion, energy failure, and parthanatos—a PARP1-dependent cell death pathway[3].
PARP1 is a multi-domain protein with distinct functional regions:
PARP1 functions as a primary DNA damage sensor, rapidly binding to single-strand breaks (SSBs), double-strand breaks (DSBs), and other DNA lesions[1:1]. Upon DNA binding, PARP1 catalytic activity increases 500-fold, synthesizing PAR chains on itself (automodification) and target proteins[8]. This PARylation:
Beyond DNA repair, PARP1 regulates gene expression through[9]:
Under oxidative stress, PARP1 can translocate to mitochondria where it[10]:
In neurodegenerative conditions, chronic DNA damage from oxidative stress leads to sustained PARP1 activation[3:1]. This creates a pathological cascade:
This mechanism has been documented in Alzheimer's disease, Parkinson's disease, Huntington's disease, and ALS[11].
Parthanatos is a distinct form of programmed cell death initiated by PARP1 hyperactivation[12]:
| Step | Molecular Event |
|---|---|
| 1 | PARP1 hyperactivation from severe DNA damage |
| 2 | Massive PAR polymer synthesis |
| 3 | PAR translocation to cytosol |
| 4 | PAR binding to AIF (apoptosis-inducing factor) |
| 5 | AIF release from mitochondria |
| 6 | AIF nuclear translocation |
| 7 | Large-scale DNA fragmentation (~50 kb) |
| 8 | Chromatin condensation and cell death |
Unlike apoptosis, parthanatos is caspase-independent and results from metabolic catastrophe rather than proteolytic cascades[13].
In AD, PARP1 hyperactivation occurs due to[14]:
PARP1 activation contributes to[15]:
PD-associated PARP1 activation results from[16]:
MPTP and 6-OHDA models show PARP1-dependent neuronal death, supporting a causal role[17].
Mutant huntingtin increases oxidative DNA damage, leading to PARP1 hyperactivation[18]. PARP inhibitors rescue HD models, suggesting therapeutic potential.
SOD1 mutations cause oxidative stress and DNA damage. PARP1 activation correlates with disease severity in ALS models and patients[19].
Several PARP inhibitors have shown neuroprotective effects in preclinical studies[20]:
| Inhibitor | Status | Key Findings |
|---|---|---|
| Olaparib | FDA-approved (cancer) | Neuroprotection in MPTP/PD models; crosses BBB |
| Niraparib | FDA-approved (cancer) | Reduces neuroinflammation; good brain penetration |
| Rucaparib | FDA-approved (cancer) | Inhibits PARP1/2/3; moderate BBB penetration |
| Veliparib | Clinical trials (cancer) | Good oral bioavailability; neuroprotective in models |
| PJ34 | Preclinical | Potent PARP1 inhibitor; neuroprotection in AD/PD models |
| Partner Protein | Function | Disease Relevance |
|---|---|---|
| XRCC1 | Base excision repair scaffold | DNA repair deficiency |
| AIF | Mediates parthanatos | Cell death execution |
| NF-κB | Transcription factor PARylation | Neuroinflammation |
| p53 | Tumor suppressor PARylation | DNA damage response |
| Histones | Chromatin PARylation | Gene regulation |
Langelier et al. PARP1 structural biology and biochemistry. Molecular Cell. 2018. ↩︎ ↩︎
Schreiber et al. Poly(ADP-ribose): novel functions for an old molecule. Nature Reviews Molecular Cell Biology. 2006. ↩︎
Fatokun et al. Parthanatos: mitochondrial-linked PARP1-dependent cell death. Neuropharmacology. 2014. ↩︎ ↩︎
Eustermann et al. Structural basis of detection and signaling of DNA single-strand breaks by PARP1. Molecular Cell. 2015. ↩︎
Altmeyer et al. Molecular mechanism of poly(ADP-ribosyl)ation by PARP1. Nature Reviews Molecular Cell Biology. 2015. ↩︎
Langelier et al. The WGR domain of PARP1. Nature Structural & Molecular Biology. 2011. ↩︎
Lord & Ashworth. PARP inhibitors: synthetic lethality in the clinic. Science. 2017. ↩︎
Benjamin & Gill. [Poly(ADP-ribose) synthesis in vitro and in vivo](https://doi.org/10.1016/0076-6879(80). Methods in Enzymology. 1980. ↩︎
Kraus. PARP1 and gene regulation. Current Opinion in Cell Biology. 2015. ↩︎
Rossi et al. Mitochondrial localization of PARP1. Journal of Cellular Biochemistry. 2009. ↩︎
Martire et al. PARP1 in neurodegeneration. Molecular Neurobiology. 2015. ↩︎
Wang et al. Parthanatos: A new form of programmed cell death. Molecular and Cellular Neurosciences. 2015. ↩︎
David et al. Parthanatos: a cell death pathway combining apoptosis and necrosis features. Cell Cycle. 2011. ↩︎
Love et al. [PARP activation in Alzheimer's disease](https://doi.org/10.1016/0197-4580(99). Neurobiology of Aging. 1999. ↩︎
Strosznajder et al. Poly(ADP-ribose) polymerase-1 in amyloid-β toxicity. Amino Acids. 2012. ↩︎
Sohur et al. PARP activation in Parkinson's disease models. Neurochemistry International. 2005. ↩︎
Iwashita et al. [PARP inhibitors and MPTP neurotoxicity](https://doi.org/10.1016/s0076-6879(97). Methods in Enzymology. 1997. ↩︎
Cardinale et al. PARP1 activation in Huntington's disease. Molecular Neurobiology. 2015. ↩︎
Kim et al. PARP1 activation in ALS motor neurons. Acta Neuropathologica. 2014. ↩︎
Morales et al. Review of PARP inhibitors in neurodegeneration. International Journal of Molecular Sciences. 2021. ↩︎
Abdellatif et al. NAD+ boosting combined with PARP inhibition. Journal of Neurochemistry. 2021. ↩︎